Josep Tabernero, MD

Vall d’Hebron University Hospital
Barcelona, Spain

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and he is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO) and Professor of Medicine at UVic-UCC. He has been Principal Investigator of several Phase I pharmacodynamic studies and translational projects with tumor-directed targeted therapies and immune therapies.
Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery, Clinical Cancer Research, Cancer Treatment Reviews and Nature Reviews in Clinical Oncology. He has (co) authored approximately 500 peer-reviewed papers.
He was the President of the European Society for Medical Oncology (ESMO) for the term 2018-2019, and is also member of the American- Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). He has also been a member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, TAT and WCGIC meetings.

Presentation(s):

• Welcome and Introduction

  Wednesday, June 29, 2022
  13:00 – 13:05

• Session I: Opening Session

  Wednesday, June 29, 2022
  13:00 – 13:30

• New Therapy for Colorectal Cancer

  Wednesday, June 29, 2022
  19:20 – 19:35

• Session VIB: Multidisciplinary Case Discussion on Oligometastatic GI Cancer

  Thursday, June 30, 2022
  08:00 – 09:25

• WCGIC Colloquium 2: Molecular Marker Platforms

  Thursday, June 30, 2022
  18:50 – 19:50

• New Mechanistic Opportunities for Antibodies

  Friday, July 1, 2022
  09:30 – 09:55

• See the Difference: Clinical Implications of BRAFV600E-mutant Metastatic CRC

  Friday, July 1, 2022
  13:40 – 15:10

• Welcome and Introduction

  Friday, July 1, 2022
  13:40 – 13:45

• One Size Does Not Fit All | Understanding the Difference

  Friday, July 1, 2022
  13:45 – 13:55

• Clinical Conversations | Case-based Discussions to Optimise the Management of BRAFV600E-mutant metastic CRC

  Friday, July 1, 2022
  13:55 – 15:05

• Closing

  Friday, July 1, 2022
  15:05 – 15:10

• Session XIX: Presentation of Selected Abstracts on GI Cancer

  Saturday, July 2, 2022
  08:15 – 09:25

• Session XXIII: Rare GI Tumors – NETs, GISTs, and Anal Cancer

  Saturday, July 2, 2022
  15:15 – 16:30

• Concluding Remarks

  Saturday, July 2, 2022
  16:25 – 16:30